A meta-analysis by Tong et al. reported that the APOC3 polymorphism rs2854116 might be involved in the development of NAFLD and could be a potential therapeutic target for NAFLD [54]. The gene discussed is APOC3; the disease is metabolic dysfunction-associated steatotic liver disease.